Atossa Therapeutics, Inc. (ATOS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated January 20, 2026, details a Special Meeting of Stockholders held by Atossa Therapeutics, Inc. The primary purpose of the meeting was to approve a material modification to the rights of security holders via a reverse stock split.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on corporate governance actions regarding capital structure.
Material Changes
- Reverse Stock Split Approval: Stockholders approved a 15:1 reverse stock split of the Company's common stock.
- Effective Date: The split is effective at 12:01 a.m. Eastern Time on February 2, 2026.
- Trading Adjustments: Common stock will commence trading on a split-adjusted basis on February 2, 2026, under the symbol "ATOS" with a new CUSIP number (04962H704).
- Fractional Shares: No fractional shares will be issued; holders will receive cash in lieu of fractions based on the closing price on January 30, 2026.
- Equity Adjustments: Proportionate adjustments will be made to outstanding equity awards, exercise prices, and the conversion price of Series B Convertible Preferred Stock.
Voting Results
As of the record date (December 19, 2025), 129,171,424 shares were entitled to vote. The amendment was approved with the following results:
- Votes For: 33,724,885
- Votes Against: 27,888,393
- Abstentions: 130,938
- Broker Non-Votes: 0
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, operational outlook, or specific risk factors beyond the standard disclosure that the description of the amendment is subject to the full text of the attached Certificate of Amendment.
Investor Verification Checklist
- Verify the new CUSIP number (04962H704) for the common stock effective February 2, 2026.
- Confirm the cash payment calculation for fractional shares based on the January 30, 2026 closing price.
- Review the impact of the 15:1 ratio on existing equity awards and Series B Convertible Preferred Stock conversion prices.
- Monitor the stock price performance on the Nasdaq Capital Market following the split-adjusted trading commencement.